Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	147059-75-4
Formula :	C₂₁H₁₉F₃N₄O₆S
M.W :	512.46
SMILES Code :	O=C(C1=CN(C2=CC=C(F)C=C2F)C3=C(C=C(F)C(N4C[C@@]5([H])[C@H](N)[C@@]5([H])C4)=N3)C1=O)O.CS(=O)(O)=O
Synonyms :	Trovafloxacin (mesylate); CP 99,219
MDL No. :	MFCD00913361

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H314-H361
Precautionary Statements:	P201-P202-P260-P264-P280-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P308+P313-P363-P405-P501
Class:	8
UN#:	1759
Packing Group:	Ⅱ

Streptococcus pneumoniae (ciprofloxacin-resistant strain P-18316)	4/8 mg/ml (MIC/MBC)	18 hours	Evaluate the in vitro activity of Trovafloxacin against ciprofloxacin-resistant strains, showing MIC of 4 mg/ml and MBC of 8 mg/ml.	Antimicrob Agents Chemother. 1998 Apr;42(4):862-7
Streptococcus pneumoniae (penicillin-resistant strains P-54988, P-12698, P-15986)	0.125/0.25 mg/ml (MIC/MBC)	18 hours	Evaluate the in vitro activity of Trovafloxacin against penicillin-resistant strains, showing MIC of 0.125 mg/ml and MBC of 0.25 mg/ml.	Antimicrob Agents Chemother. 1998 Apr;42(4):862-7
Streptococcus pneumoniae (penicillin-susceptible strain P-4241)	0.06/0.25 mg/ml (MIC/MBC)	18 hours	Evaluate the in vitro activity of Trovafloxacin against penicillin-susceptible strains, showing MIC of 0.06 mg/ml and MBC of 0.25 mg/ml.	Antimicrob Agents Chemother. 1998 Apr;42(4):862-7
Escherichia coli	0.25 µg/ml	24 hours	To evaluate the antimicrobial effect of Trovafloxacin against E. coli, showing an MIC of 0.25 µg/ml.	Antimicrob Agents Chemother. 1999 Mar;43(3):498-502
Staphylococcus aureus	0.15 µg/ml	24 hours	To evaluate the antimicrobial effect of Trovafloxacin against S. aureus, showing an MIC of 0.15 µg/ml.	Antimicrob Agents Chemother. 1999 Mar;43(3):498-502
Bacteroides fragilis ATCC 23745 co-cultured with Vancomycin-Resistant Enterococcus faecium (VREF)	2 μg/ml	24 hours	To study the bactericidal effect of Trovafloxacin on Bacteroides fragilis in mixed culture, results showed a 14-fold increase in concentration was required to achieve similar killing as in pure culture.	Antimicrob Agents Chemother. 2001 Jan;45(1):243-51
Bacteroides fragilis ATCC 23745 co-cultured with Escherichia coli ATCC 25922	1 μg/ml	24 hours	To study the bactericidal effect of Trovafloxacin on Bacteroides fragilis in mixed culture, results showed maximum bactericidal effect (Emax >6.1 log10CFU/ml) within 24 hours.	Antimicrob Agents Chemother. 2001 Jan;45(1):243-51
Bacteroides fragilis ATCC 23745	0.5 μg/ml	24 hours	To study the bactericidal effect of Trovafloxacin on Bacteroides fragilis, results showed maximum bactericidal effect (Emax >6.1 log10CFU/ml) within 24 hours.	Antimicrob Agents Chemother. 2001 Jan;45(1):243-51
Streptococcus mitis	0.125 mg/ml	24 hours	Evaluate the bactericidal effect of Trovafloxacin on S. mitis, showing potent killing after 24 hours.	Antimicrob Agents Chemother. 2000 Sep;44(9):2554-6
Streptococcus sanguis	0.125 mg/ml	24 hours	Evaluate the bactericidal effect of Trovafloxacin on S. sanguis, showing less than a 2-log10 CFU/ml reduction after 24 hours.	Antimicrob Agents Chemother. 2000 Sep;44(9):2554-6
Enterococcus faecium	3 mg/L	24 hours	To evaluate the bactericidal activity of Trovafloxacin against vancomycin-resistant enterococci. Results showed that for strains with MICs ≤2 mg/liter, Trovafloxacin reduced viable counts by 1-3 log units at 24 hours.	Antimicrob Agents Chemother. 1998 Jan;42(1):72-7
Bacteroides fragilis M97-117	0.02 to 34.7 µg/ml	24 hours	To evaluate the bactericidal effect of Trovafloxacin on Bacteroides fragilis. Results showed that the bactericidal effect was maximized when the AUC0–24/MIC ratio was >40, and further increases in the AUC0–24/MIC ratio did not significantly enhance the bactericidal effect.	Antimicrob Agents Chemother. 2002 Jan;46(1):203-10
Bacteroides fragilis ATCC 23745	0.02 to 34.7 µg/ml	24 hours	To evaluate the bactericidal effect of Trovafloxacin on Bacteroides fragilis. Results showed that the bactericidal effect was maximized when the AUC0–24/MIC ratio was >40, and further increases in the AUC0–24/MIC ratio did not significantly enhance the bactericidal effect.	Antimicrob Agents Chemother. 2002 Jan;46(1):203-10
Bacteroides fragilis ATCC 25285	0.02 to 34.7 µg/ml	24 hours	To evaluate the bactericidal effect of Trovafloxacin on Bacteroides fragilis. Results showed that the bactericidal effect was maximized when the AUC0–24/MIC ratio was >40, and further increases in the AUC0–24/MIC ratio did not significantly enhance the bactericidal effect.	Antimicrob Agents Chemother. 2002 Jan;46(1):203-10
Human monocytes	1, 5, or 10 µg/ml	24 hours	Suppressed cytokine production (IL-1α, IL-1β, IL-6, IL-10, GM-CSF, TNF-α) by LPS- or Pansorbin-stimulated monocytes	Antimicrob Agents Chemother. 1998 Jul;42(7):1713-7
BV-2 cells	1 µM	30 minutes	To evaluate whether trovafloxacin blocks ATP release and cell migration in a chemotactic-stimulated microglial cell line. It was found that trovafloxacin significantly inhibited both ATP release and migration of these cells.	J Neuroinflammation. 2018 Feb 13;15(1):42
Second-step mutants of S. pneumoniae	32–256 μg/ml (ciprofloxacin), 4–16 μg/ml (trovafloxacin)	48 hours	Secondary mutations in GyrA (Ser84→Tyr/Phe or Glu88→Lys) conferred high-level resistance to trovafloxacin (MIC 4–16 μg/ml).	Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7
First-step mutants of S. pneumoniae	4–8 μg/ml (ciprofloxacin), 0.5 μg/ml (trovafloxacin)	48 hours	Selected ciprofloxacin-resistant mutants via stepwise exposure. GrlA (topoisomerase IV) Ser80→Phe/Tyr mutations increased trovafloxacin MIC to 0.5 μg/ml.	Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7
Clinical isolates of S. pneumoniae	0.063–0.25 μg/ml (MIC90)	48 hours	Determined antibacterial activity against S. pneumoniae, showing trovafloxacin's superior potency (MIC90 0.125 μg/ml) compared to other fluoroquinolones.	Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7
Vancomycin-intermediate Staphylococcus aureus (VISA) 992	1 mg/ml (MIC)	48 hours	To evaluate the antibacterial activity of Trovafloxacin against VISA strains. Trovafloxacin (200 mg) produced only slight killing of all three VISA strains, with regrowth observed by 24 h. The higher dose of Trovafloxacin (400 mg) improved killing but did not produce bactericidal activity at 48 h.	Antimicrob Agents Chemother. 2000 May;44(5):1153-8
Vancomycin-intermediate Staphylococcus aureus (VISA) Mu50	2 mg/ml (MIC)	48 hours	To evaluate the antibacterial activity of Trovafloxacin against VISA strains. Trovafloxacin (200 mg) produced only slight killing of all three VISA strains, with regrowth observed by 24 h. The higher dose of Trovafloxacin (400 mg) improved killing but did not produce bactericidal activity at 48 h.	Antimicrob Agents Chemother. 2000 May;44(5):1153-8
Vancomycin-intermediate Staphylococcus aureus (VISA) 14379	0.5 mg/ml (MIC)	48 hours	To evaluate the antibacterial activity of Trovafloxacin against VISA strains. Trovafloxacin (200 mg) produced only slight killing of all three VISA strains, with regrowth observed by 24 h. The higher dose of Trovafloxacin (400 mg) improved killing but did not produce bactericidal activity at 48 h.	Antimicrob Agents Chemother. 2000 May;44(5):1153-8
Streptococcus pneumoniae	0.06 to 0.6 μg/ml	6 hours	To test the bactericidal activity of Trovafloxacin against penicillin-highly resistant Streptococcus pneumoniae. Results showed that Trovafloxacin had good bactericidal activity when concentrations were above the MIC.	Antimicrob Agents Chemother. 1999 Apr;43(4):963-5
Hepa1c1c7 cells	200 µM	6 or 24 hours	TVX enhanced TNF-induced Hepa1c1c7 cell death and caspase 3/7 activity.	Toxicol Sci. 2009 Oct;111(2):288-301
HepG2 cells	20 µM	6, 12, 24 hours	To explore the mechanism by which TVX interacts with TNF to cause cytotoxicity. TVX caused cell cycle arrest, enhanced p21 expression and impaired proliferation, but cell death only occurred after cotreatment with TVX and TNF. Cell death involved ERK activation, which in turn activated caspase 3 and ATR, both contributing to cytotoxicity.	Toxicology. 2015 May 4;331:35-46

{[proInfo.proName]}

CAS No.: 147059-75-4

{[proInfo.proName]}

CAS No.: 147059-75-4

Alternative Products

Product Details of Trovafloxacin mesylate

Safety of Trovafloxacin mesylate

Related Pathways of Trovafloxacin mesylate

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Mice	Lethal S. pneumoniae lung infection model	Oral	12 mg/kg	Twice daily for 3 days	Evaluated efficacy against wild-type and GrlA mutant infections. Despite mutant MIC increase (0.5 μg/ml), PD50 only rose 1.9-fold (11.1 mg/kg vs 6.0 mg/kg). Drug levels exceeded MIC in lungs for >20 hours.	Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7
Swiss mice	Immunocompetent mice (penicillin-susceptible strain P-4241) and leukopenic mice (penicillin-resistant strains P-54988, P-12698, P-15986 and ciprofloxacin-resistant strain P-18316)	Subcutaneous injection	12.5-300 mg/kg	Every 8 or 12 hours for 3 days	Evaluate the in vivo efficacy of Trovafloxacin in a mouse pneumonia model against penicillin-susceptible and -resistant S. pneumoniae. Results showed that Trovafloxacin (25 mg/kg) provided 2- to 4-fold higher survival rates than sparfloxacin (50 mg/kg) or temafloxacin (50 mg/kg) and 8- to 16-fold higher than ciprofloxacin (100 mg/kg) against penicillin-susceptible and -resistant strains. The AUC/MIC ratios in serum and lung tissue were more favorable with trovafloxacin than with other quinolones.	Antimicrob Agents Chemother. 1998 Apr;42(4):862-7
New Zealand White rabbits	Experimental endocarditis model	Intravenous injection	15 mg/kg	Three times daily for 3 days	Evaluate the therapeutic effect of Trovafloxacin in an experimental endocarditis model, showing less efficacy against S. sanguis infection compared to vancomycin or penicillin but similar efficacy against S. mitis infection.	Antimicrob Agents Chemother. 2000 Sep;44(9):2554-6
New Zealand White rabbits	Rabbit meningitis model	Intravenous injection	15 mg/kg	Single dose, duration of 8 hours	To evaluate the therapeutic effect of Trovafloxacin alone or in combination with vancomycin against meningitis caused by penicillin-highly resistant Streptococcus pneumoniae. Results showed that Trovafloxacin alone had moderate bactericidal activity, and the combination with vancomycin significantly enhanced the bactericidal activity.	Antimicrob Agents Chemother. 1999 Apr;43(4):963-5
White rabbits	Experimental streptococcal aortic valve endocarditis	Intravenously	15 mg/kg (single dose) and 15 mg/kg (double dose, 7 hours apart)	Single dose or double dose (7 hours apart), lasting 72 hours	Evaluate the prophylactic efficacy of Trovafloxacin against streptococcal endocarditis. Single-dose Trovafloxacin protected 38% of animals, while double-dose Trovafloxacin provided 100% protection.	Antimicrob Agents Chemother. 2000 Sep;44(9):2564-6
C57Bl/6J mice	Mouse model	Oral	150 mg/kg	Single dose	TVX pretreatment prolonged the peak of plasma TNF concentration and enhanced TNF-induced inflammatory stress and cell death signaling.	Toxicol Sci. 2009 Oct;111(2):288-301
CF1 mice	Acute systemic infection model	Oral	25 mg/kg	Single dose	To evaluate the pharmacokinetic properties of Trovafloxacin in an acute systemic infection model, showing significantly higher concentrations in lung tissue compared to serum and a longer half-life.	Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6
Swiss Webster mice	Acute murine toxoplasmosis model	Oral	25 mg/kg/day	Once daily for 10 days	To evaluate the synergistic effects of Trovafloxacin in combination with other anti-toxoplasma drugs. Results showed that combinations of trovafloxacin with clarithromycin, pyrimethamine, or sulfadiazine significantly enhanced survival rates in mice.	Antimicrob Agents Chemother. 1997 May;41(5):893-7
BALB/c mice	Subcutaneous abscess model	Subcutaneous injection	37.5 to 300 mg/kg/day	Every 8 hours or every 24 hours for 3 or 5 days	To evaluate the efficacy of Trovafloxacin in treating mixed infections of B. fragilis-E. coli and B. fragilis-VREF abscesses. Results showed that Trovafloxacin significantly reduced bacterial counts, abscess weight, and inflammation for B. fragilis and E. coli, but was ineffective against VREF.	Antimicrob Agents Chemother. 2001 May;45(5):1394-401
Mice	Controlled cortical impact model	Intraperitoneal injection	60 mg/kg	Administered at 1, 24, and 48 hours post-injury	To test whether trovafloxacin administration attenuates the neuroinflammatory response and improves outcomes after brain trauma. It was found that trovafloxacin significantly reduced tissue damage markers and improved locomotor deficits.	J Neuroinflammation. 2018 Feb 13;15(1):42
Sprague-Dawley rats	Acute Pseudomonas aeruginosa pneumonia model	Intraperitoneal injection	75 mg/kg	Every 5 hours, total 3 times	To compare the ability of Trovafloxacin and Ciprofloxacin to select efflux mutants in vivo	Antimicrob Agents Chemother. 2001 Feb;45(2):571-6
Rats	Sprague-Dawley rats	Intravenous and oral	intravenous 10 mg/kg, oral 50 mg/kg	Single dose	To characterize the pharmacokinetics of trovafloxacin in rats, dogs, and monkeys, including absorption, distribution, metabolism, and excretion. Results showed that trovafloxacin had good oral bioavailability (rats 68%, dogs 58%, monkeys 85%) and was primarily excreted through bile.	Antimicrob Agents Chemother. 1996 Mar;40(3):561-6
Dogs	Purebred beagle dogs	Intravenous and oral	intravenous 5 mg/kg, oral 20 mg/kg	Single dose	To characterize the pharmacokinetics of trovafloxacin in rats, dogs, and monkeys, including absorption, distribution, metabolism, and excretion. Results showed that trovafloxacin had good oral bioavailability (rats 68%, dogs 58%, monkeys 85%) and was primarily excreted through bile.	Antimicrob Agents Chemother. 1996 Mar;40(3):561-6
Monkeys	Cynomolgus monkeys	Intravenous and oral	intravenous and oral 20 mg/kg	Single dose	To characterize the pharmacokinetics of trovafloxacin in rats, dogs, and monkeys, including absorption, distribution, metabolism, and excretion. Results showed that trovafloxacin had good oral bioavailability (rats 68%, dogs 58%, monkeys 85%) and was primarily excreted through bile.	Antimicrob Agents Chemother. 1996 Mar;40(3):561-6

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.95mL 0.39mL 0.20mL	9.76mL 1.95mL 0.98mL	19.51mL 3.90mL 1.95mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed